新华制药(000756) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was approximately CNY 3.55 billion, representing an increase of 8.07% compared to the same period last year[14]. - The total profit for the reporting period was approximately CNY 260.36 million, reflecting a year-on-year increase of 12.70%[14]. - The net profit attributable to shareholders of the listed company was approximately CNY 200.08 million, which is a 16.12% increase compared to the previous year[14]. - The net profit after deducting non-recurring gains and losses was approximately CNY 185.86 million, up by 20.47% year-on-year[14]. - The basic earnings per share for the reporting period was CNY 0.32, an increase of 14.29% compared to the same period last year[14]. - The total revenue for the reporting period reached RMB 3,551,043,752.95, representing an increase of 8.07% compared to RMB 3,285,772,716.57 in the same period last year[66]. - The total comprehensive income for the first half of 2021 was RMB 171,687,869.96, compared to RMB 140,225,562.96 in the previous year, reflecting an increase of 22.47%[141]. - The company's total equity as of June 30, 2021, was RMB 2,941,392,330.37, slightly up from RMB 2,900,622,666.04 at the end of 2020, showing a growth of 1.41%[139]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately CNY 7.27 billion, an increase of 2.52% from the end of the previous year[14]. - The total liabilities at the end of the reporting period were approximately CNY 3.75 billion, reflecting a 1.23% increase compared to the previous year[14]. - The total liabilities reached RMB 3,747,286,649.76, slightly up from RMB 3,701,662,448.12, reflecting a marginal increase of 1.2%[135]. - The total current liabilities amounted to RMB 2,507,368,417.07, an increase from RMB 2,381,039,242.59 as of December 31, 2020, representing a growth of approximately 5.3%[135]. - The total non-current liabilities decreased to RMB 1,239,918,232.69 from RMB 1,320,623,205.53, indicating a reduction of about 6.1%[135]. Cash Flow - The net cash flow from operating activities was approximately CNY 165.10 million, a decrease of 17.70% compared to the same period last year[14]. - The cash and cash equivalents net increase decreased by 74.72%, highlighting a decline in cash inflow from financing activities[64]. - The net cash flow from operating activities for the current period is RMB 87,524,492.14, a decrease of 45.8% compared to RMB 161,203,550.66 in the previous period[148]. - Cash inflow from financing activities is RMB 485,704,800.00, down 46.0% from RMB 899,500,000.00 in the previous period[148]. Research and Development - The company increased R&D investment to RMB 164 million in the first half of the year, a year-on-year growth of 10.28%[40]. - Research and development expenses increased by 10.28% to RMB 163,835,401.81, indicating a focus on innovation[60]. - Research and development expenses for the first half of 2021 were RMB 170,257,317.76, compared to RMB 157,166,732.04 in the same period of 2020, representing an increase of 8.93%[141]. - The company obtained 6 drug approvals, including Erbesartan, and has 10 products awaiting review at CDE[40]. Market Performance - The export sales of key raw materials such as EPA and hormone products increased by 86% and 216.8% respectively, while the export volume of solid preparations to the UK and Europe grew by 26.05%[38]. - Domestic sales of raw materials reached RMB 461 million, marking a 17.44% increase year-over-year, with new veterinary drug product sales up by 50%[38]. - The company's formulation products generated sales revenue of RMB 824 million, a 12.36% increase, with ten strategic formulation varieties seeing a 32.5% rise in sales volume[39]. - The company achieved export revenue of $174.51 million in the first half of 2021, with exposure to currency fluctuation risks[78]. Environmental Compliance - The company adheres to national environmental policies and will increase investment in environmental protection facilities[89]. - The company has not faced administrative penalties for environmental issues during the reporting period[92]. - The company operates as a key pollutant discharge unit, with specific measures in place to monitor and control emissions[93]. - Wastewater discharge standards are being met, with no exceedances reported for chemical oxygen demand and ammonia nitrogen[93]. - The company has implemented safety and environmental training to reduce environmental risks and ensure compliance[89]. Corporate Governance - The company has established a governance framework and confirmed compliance with corporate governance codes as of June 30, 2021[128]. - The audit committee has reviewed the accounting principles and methods adopted by the group for the six months ending June 30, 2021, and has agreed with the financial statements presented[129]. - The financial statements are prepared based on the going concern assumption, with no significant doubts about the company's ability to continue operations[165]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[8]. - The board of directors recommended not to distribute dividends for the first half of 2021, maintaining a conservative financial strategy[85]. - As of June 30, 2021, the total number of shareholders was 32,152, including 46 H-share shareholders and 32,106 A-share shareholders[18]. - The top ten shareholders held a total of 204,864,092 shares, accounting for 32.65% of the total shares[19].